Basic introduction and marketing related information of ADAMTS13 recombinant protease (trade name: Apadase α, English: Adzynma)

Adzynma (ADAMTS13, recombinant - krhn) is a highly innovative drug that belongs to the human recombinant "disintegrin and metalloproteinase with thrombospondin motif 13" ADAMTS13 (rADAMTS13). In the medical field, it has precise and critical applicable scenarios, mainly for adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). Whether used as a preventive treatment or on-demand enzyme replacement therapy (ERT), Adzynma can play an important role with its unique pharmacological mechanism, bringing a new dawn of recovery to patients suffering from diseases.

Adzynma has received many honors and recognitions in the process of drug development and identification. The U.S. FDA has granted it Orphan Drug Designation (ODD). This honor shows that it has irreplaceable value in the treatment and prevention of thrombotic thrombocytopenic purpura (TTP). Its scope of application is wide, covering a variety of complex diseases such as acquired idiopathic and secondary forms. At the same time, it also received Fast Track and Rare Pediatric Disease designations, which highlights its urgency and importance in addressing rare diseases, especially pediatric rare diseases. Takeda has obtained a rare pediatric disease certificate from the U.S. FDA for Adzynma, which adds strong guarantee for the smooth approval of the drug.

Not only that,Adzynma’s influence also transcends national borders. The European Medicines Agency (EMA) and the Japanese Ministry of Health, Labor and Welfare (MHLW) also granted it orphan drug designation for the treatment of TTP. This series of international recognitions not only proves Adzynma's important position in the global medical field, but also paves the way for its application and promotion in different countries and regions, which is expected to allow more patients to benefit from this innovative drug.

Currently,ADAMTS13 recombinant protease has not yet been launched in the country. However, China has prioritized its inclusion in the review process and accelerated its domestic listing. I believe that it won’t be long before domestic patients will be able to use this drug. If patients want more information about this drug, they can contact their medical advisor.

Reference link:https://www.drugs.com/newdrugs/fda-approves-adzynma-adamts13-recombinant-krhn-enzyme-replacement-therapy-congenital-thrombotic-6141.html